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Abstract
Background:  Connective  tissue  diseases  (CTD)  are  frequently  associated  with  interstitial  lung
disease (ILD),  significantly  impacting  their  morbidity  and  mortality.
Aim:  Analyze  the  experience  of  an  autoimmune  specialized  unit  on  treating  CTD-ILD  and  char-
acterize  the  population  based  on  most  frequent  diseases,  imaging  patterns,  lung  function  tests
results, serology  and  treatment.  Assess  mortality  and  mortality  predictors  in  these  patients.
Methods: Retrospective,  descriptive  and  statistical  analysis  of  the  CTD-ILD  patients  followed
up at  an  autoimmune  diseases  unit  during  a  6-year  period.
Results:  Over  the  study  period,  75  patients  with  CTD-ILD  were  treated  with  a  mean  follow-up
of 49  ±  31  months.
The  most  frequent  CTD  were  systemic  sclerosis  and  rheumatoid  arthritis.  ILD  was  diagnosed
prior to  CTD  in  8%  of  patients  and  concomitantly  in  35%.  Nonspecific  interstitial  pneumonia
was the  CT  pattern  in  60%  and  35%  had  an  isolated  diminished  DLCO  on  lung  function  tests.
Pulmonary  hypertension  was  present  in  12%  and  it  was  the  single  most  important  mortality
predictor  (OR  14.41,  p  =  0.006).  Corticosteroids  are  the  mainstay  of  treatment  but  biologics
were prescribed  in  39%  of  the  patients  (mostly  tocilizumab  and  rituximab).  Two  scleroderma
patients were  recently  treated  with  nintedanib.
Conclusions:  ILD  is  a  potential  complication  of  every  CTD  and  can  impose  a  dramatic  burden  on
these patients.  The  clinical  relevance  of  ILD  together  with  their  early  expression  in  the  course
of the  disease  underlines  the  importance  of  the  presence  of  chest  physicians  in  these  units.
© 2020  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Please  cite  this  article  in  press  as:  Oliveira  RP,  et  al.  Pulmonol.
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ntroduction
onnective  tissue  diseases  (CTD)  are  a  group  of  diseases  with
eterogeneous  systemic  features  and  immune-mediated
ulti-organ  disfunction.  The  respiratory  tract  can  be
argeted  in  virtually  every  CTD  and  with  a  multitude  of  man-
festations,  bringing  important  implications  to  the  diagnosis,
ollow-up,  treatment  and  prognosis  of  these  patients.1,2
ung  involvement  is  a  decisive  contributor  to  the  mortality
n  CTD,  and  is  now  the  leading  cause  of  death  in  systemic
clerosis  (SSc)3 and  an  increasing  cause  of  death  in  rheuma-
oid  arthritis  (RA),  even  as  the  overall  mortality  rates  are
alling.4
Interstitial  lung  disease  (ILD)  is  frequently  present  in
atients  with  autoimmune  myopathies,  SSc,  Sjögren’s  syn-
rome,  RA  and  systemic  lupus  erythematosus  (SLE),  with
stimated  prevalences  of  40%,  30--40%,  40%,  10%  and  12%,
espectively.5 It  is  important  to  keep  in  mind  that  ILD  may
e  the  only  manifestation  of  a  yet-to-be  diagnosed  CTD.6
High-resolution  computed  tomography  (HRCT)  and  pul-
onary  function  tests  (PFT)  are  the  best  tools  to  evaluate
ung  involvement  and  have  prognostic  value.7--9
While  there  are  no  definitive  serum  biomarkers  for  CTD-
LD,  the  presence  of  some  disease-specific  markers  can  lead
o  a  better  screening  and  risk-stratifying  of  patients.10
Pulmonary  hypertension  (PH)  is  a  common  finding  in  CTD-
LD  patients  and  adds  significant  impact  to  the  morbidity  and
ortality  of  these  patients.11
Development  of  lung  disease,  and  its  associated  symp-
oms  like  dyspnea  and  cough,  provides  extra  burden  on  a
roup  of  diseases  already  highly  impactful  on  quality  of
ife.12
Even  though  ILD  is  a  common  complication  of  CTD,  the
efinitive  guidance  on  how  to  treat  these  patients  is  scarce.
orticosteroids  still  represent  the  mainstay  of  treatment.13
n  the  context  of  SSc,  there  is  also  an  increasing  body  of  evi-
ence  for  biologics,  such  as  tocilizumab14 and  rituximab,15
nd  renewed  enthusiasm  for  new  therapeutical  targets,  such
s  antifibrotic  drugs.16,17
Due  to  the  sheer  complexity  and  systemic  involvement
f  these  diseases,  a  multidisciplinary  approach  should  be
he  gold-standard  when  treating  these  patients.18 This  paper
ims  to  compile,  analyze  and  discuss  the  experience  of  our
nit  in  the  management  of  CTD-ILD.
ethods
he  authors  conducted  a  retrospective,  descriptive  analy-
is  of  patients  older  than  18  years  diagnosed  with  CTD-ILD
ollowed  up  at  an  autoimmune  diseases  outpatient  clinic
etween  January  of  2013  and  December  of  2018.
The  diagnosis  of  CTD  was  based  on  clinical  and  serologic
riteria  according  to  the  most  recent  EULAR  recommenda-
ions  and  the  diagnosis  of  ILD  was  made  on  the  basis  of  HRCT
ndings.  All  patients  were  discussed  in  a  weekly  autoimmune
iseases  multidisciplinary  team  meeting.  Cases  were  further
iscussed  with  pulmonology  and  radiology  on  a  case-by-casePlease  cite  this  article  in  press  as:  Oliveira  RP,  et  al.  Pulmonol
asis.
HRCT  scans  and  PFT  results  shown  are  the  ones  done  at
he  ILD  diagnosis.  HRCT  scans  were  obtained  with  1--1.5  mm
hick  slices.  PFT  were  carried  out  according  to  a  stan-
(
p
o PRESS
R.P.  Oliveira  et  al.
ardized  protocol  in  the  respiratory  medicine  department.
tatic  lung  volumes  were  measured  using  the  plethys-
ography  method,  and  the  lung  diffusion  capacity  of  CO
DLCO)  using  the  single  breath-hold  method.  Antibodies
ere  tested  with  the  following  techniques:  ANA,  ANCA
-  indirect  immunofluorescence  assay;  Anti-SSA,  anti-SSB,
nti-Sm  -- Immunoblot  assay;  anti-dsDNA,  anti-CCP  --  fluo-
escence  enzyme  immunoassay  (FEIA);  Rheumatoid  factor  --
urbidimetry.
Data  was  collected  from  hospital  records  and  handled
n  an  anonymous  and  population-based  fashion.  Normally
istributed  variables  are  presented  as  mean  and  standard
eviation  and  non-normal  variables  are  presented  as  median
nd  interquartile  range.  Differences  in  baseline  variables
ere  tested  with  t-tests  for  continuous  variables;  2-trend
ests  for  ordered  categorical  variables;  and  2  tests  for  bino-
ial  and  unordered  categorical  variables.  Statistical  analysis
as  performed  using  Stata® 14  software.
esults
opulation
uring  the  6-year  study  period,  75  CTD-ILD  patients  were
ollowed-up  at  this  unit  with  a  mean  follow-up  of  49  ±  31
onths  amounting  to  646.2  patients-years.  The  mean  age
t  the  time  of  ILD  diagnosis  was  56  ±  15.5  years-old,  there
as  a  clear  female  predominance  (77.3%)  and  the  mean
uration  of  CTD  was  8.9  ±  7.5  years.  CTD  was  diagnosed
efore  ILD  in  57%  of  patients,  with  a  median  interval  of  49.1
23.7--127.15]  months  separating  the  two  diagnosis.  ILD  was
iagnosed  first  in  8%  of  patients  (n  =  6)  with  CTD  being  diag-
osed  shortly  after  (mean  interval  of  5.1  months).  Diagnosis
as  simultaneous  in  35%  of  patients.
The  CTD  were,  by  order  of  prevalence,  SSc  (34.7%;
 =  26),  RA  (20%;  n  =  15),  overlap  syndrome  (13.3%;  n  =  10),
ixed  CTD  (9.3%;  n  =  7),  autoimmune  myopathy  (6.7%;  n  =  5),
NCA-positive  vasculitis  (5.3%;  n  =  4),  undifferentiated  CTD
5.3%;  n  =  4)  and  Sjögren  syndrome  (2.7%;  n  =  2).
maging  and  biopsy
onspecific  interstitial  pneumonia  (NSIP)  was  the  most  com-
on  HRCT  pattern,  present  in  60%  of  patients,  followed  by
sual  interstitial  pneumonia  (UIP)  in  36%  of  patients  and  a
attern  of  lymphocytic  interstitial  pneumonia  (LIP)  in  the
emaining  3  patients.  One  patient  with  anti-synthetase  syn-
rome  had  a  predominance  of  NSIP  pattern  overlapped  with
rganizing  pneumonia  (OP)  features.  Out  of  the  patients
ith  NSIP  pattern,  42.2%  had  a  diagnosis  of  SSc  and  24.4%
ad  overlap  syndrome  or  mixed  CTD  with  a predominance
f  scleroderma  findings.  Among  patients  with  SSc,  58%  had
xtensive  disease  (>20%  involvement19) on  HRCT.  A  LIP  pat-
ern  was  found  in  2  patients  with  Sjögren  syndrome  and
 with  polymyositis.  Other  common  findings  were  pleural
hickening  (n  =  16),  lung  nodules  (n  =  14)  and  pleural  effusion.  2020.  https://doi.org/10.1016/j.pulmoe.2020.01.004
n  =  5).
While  not  mandatory  for  the  diagnosis,  lung  biopsy  was
erformed  in  11  patients  who  had  conflicting  HRCT  findings
r  a  broader  differential  diagnosis,  3  being  compatible  with
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NSIP  and  3  with  UIP.  The  remaining  5  biopsies  had  nonspecific
findings.
Pulmonary  function  tests
PFT  were  carried  out  in  all  patients  at  the  time  of  ILD  diag-
nosis.  A  restrictive  pattern  was  found  in  46%  whilst  only  6%
had  an  obstructive  pattern.  Isolated  diminished  DLCO  was
present  in  35%  of  patients  and  13%  had  all  results  within
the  normal  range.  ANCA-positive  vasculitis,  autoimmune
myopathies  and  mixed  CTD,  were  the  subgroup  of  patients
who  presented  with  more  severe  lung  involvement  at  diag-
nosis  (Table  1).
At  time  of  diagnosis  only  2  patients  had  arterial  pressure
of  oxygen  below  60  mmHg  on  room  air  and  only  3  patients
had  minor  hypercapnia.
Pulmonary  hypertension
Nine  patients  (12%)  had  signs  of  pH  on  transthoracic  echocar-
diography  (pulmonary  artery  systolic  pressure  ≥40  mmHg),
with  a  mean  pressure  of  60.8  ±  23.8  mmHg.  Five  patients  had
SSc  and  the  other  4  had  mixed  CTD  or  overlap  syndrome  with
a  predominance  of  scleroderma  findings.  Echocardiographic
data  was  missing  in  13  patients.
Five  patients  underwent  right  heart  catheterization
(RHC).  Two  of  them  did  not  have  a  confirmation  of  PH,
the  others  had  a  mean  pulmonary  artery  pressure  of
40  ±  2.1  mmHg  and  a  mean  pulmonary  vascular  resistance
of  10.4  ±  6  Wood  Units.  Of  these  3,  all  with  SSc,  1  was  clas-
sified  as  having  group  I  PH,  the  others  were  group  III.  In  the
remainder  4  patients  with  echocardiographic  signs  of  PH,
RHC  was  not  conducted  as  the  procedure  was  considered
too  risky  or  of  no  added  benefit  to  the  management  of  these
particular  patients.
Autoantibodies
Anti-nuclear  antibodies  were  positive  in  79%  of  patients
(titre  ≥1:320  in  80%).
Amongst  SSc  patients,  54%  were  anti-Scl70  positive,
15.4%  were  anti-centromere  positive  and  7.7%  were  anti-
PM-Scl  positive.
Amongst  RA  patients,  73.3%  were  simultaneously
rheumatoid  factor  (mean  value  of  338  ±  266  UI/mL)  and
anti-citrullinated  protein  (anti-CCP)  positive  (mean  value  of
170.1  ±  160.4  UI/mL)
In  overlap  syndromes,  the  most  frequently  found  sero-
logic  markers  were  anti-SSA  (present  in  40%  of  patients)
followed  by  anti-SSB,  anti-Scl70,  anti-PM-Scl,  rheumatoid
factor  and  anti-CCP  (all  present  in  20%  of  these  patients).
All  patients  classified  as  having  mixed  CTD  were  anti-RNP
positive.  Four  out  of  the  five  patients  with  autoimmunePlease  cite  this  article  in  press  as:  Oliveira  RP,  et  al.  Pulmonol.
myopathy  were  diagnosed  with  anti-synthetase  syndrome
(3  were  anti-Jo1  positive  and  the  other  was  anti-PL12  pos-
itive).  The  patient  with  polymyositis  was  anti-Ku  positive
(anti-MDA5  was  not  tested).
T
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reatment
ystemic  corticosteroids  were  by  far  the  most  used  drug,
eing  used  at  some  point  during  the  course  of  disease  in
6.7%  of  the  patients.  Mycophenolate  mofetil  was  used  in
6%  of  patients,  cyclophosphamide  in  33%  and  azathioprine
n  29.3%.  Methotrexate  (MTX)  was  used  prior  to  ILD  diagnosis
n  32%  of  patients  (n  =  23),  but  was  then  switched  to  another
mmunossupressor  drug  (mainly  mycophenolate)  in  all  but  2
atients.  Out  of  the  patients  who  were  treated  with  MTX,  3
13%)  had  lung  fibrosis  considered  to  be  caused  by  the  drug.
Biologic  drugs  were  used  in  39%  of  the  patients,  with
ocilizumab  and  rituximab  being  the  most  used  as  first-
ine  therapy  (13  patients  each),  followed  by  etanercept  (3
atients).  Sixty  percent  of  the  patients  with  RA  were  on
iologic  treatment,  as  were  23.1%  of  SSc.  Tocilizumab  was
he  most  used  biologic  in  RA  but  this  decision  was  driven
y  joint  disease  in  all  but  one  patient.  All  patients  with
NCA-positive  vasculitis  and  anti-synthetase  syndrome  were
n  rituximab  (Table  1).  Five  patients  required  a  biologic
witch  due  to  failure  of  first-line  choice  (3  patients  were
witched  from  tocilizumab  to  rituximab,  2  patients  were
witched  from  etanercept  to  tocilizumab).  In  3  of  these
atients  the  switch  was  decided  based  on  ILD  progression,  in
he  other  2  patients  the  decision  was  made  due  to  ongoing
ctivity  of  the  joint  involvement  (both  patients  had  overlap
yndrome).  Throughout  the  follow-up  period  there  were  no
xacerbations  of  the  ILD  caused  by  the  starting  of  biologic
reatment.
Two  patients  with  SSc  were  recently  treated  with
intedanib  (one  with  UIP  pattern,  the  other  NSIP).
Six  patients  of  the  nine  diagnosed  with  pH  were  pre-
cribed  specific  treatment  targeted  at  PH:  3  bonsentan,  1
lprostadil,  1  iloprost  and  1  sildenafil.  The  last  two  patients
ere  later  switched  to  bonsentan.
ortality
his  cohort  had  a  mortality  rate  of  20%  (15/75  patients)  dur-
ng  the  analyzed  period,  with  a  mean  survival  of  67.8  ±  57.3
onths  since  CTD  diagnosis  and  37.8  ±  20.9  months  since
LD  diagnosis.  Mortality  rate  was  higher  in  RA  and  overlap
yndrome  (Table  1).
Comparing  deceased  patients  with  the  survivors,  the  first
roup  was  older  at  the  time  of  CTD  diagnosis  (58.6  ±  4.9
s  51.5  ±  2.7  years-old,  p  =  0.23),  older  at  the  time  of  last
ollow-up  (66.4  ±  11.1  vs  60.4  ±  15.2  years-old,  p =  0.03)  and
ore  frequently  male  (33  vs  20%,  p  =  0.31).  UIP  pattern  on
RCT  was  related  with  higher  mortality  but  the  difference
as  not  significant.  There  were  no  significant  differences
egarding  other  imaging  patterns,  diagnosis  of  SSc,  corti-
otherapy  and  ANA  positivity.  The  presence  of  pH  was  clearly
ssociated  with  higher  mortality  (OR  14.41,  p  =  0.006)  and  so
as  the  use  of  biologics  (OR  5.56,  p  0.025).
iscussion 2020.  https://doi.org/10.1016/j.pulmoe.2020.01.004
his  population  of  75  CTD-ILD  patients  constitutes  a  rel-
vant  sized  population  with  a  long  mean  follow-up  time
f  49  ±  31  months  over  the  span  of  6  years.  ILD  was  diag-
osed  prior  to  CTD  in  only  8%  of  patients  but  this  is  probably
ARTICLE IN PRESS+ModelPULMOE-1439; No. of Pages 6
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Table  1  Description  of  main  characteristics  analyzed  by  disease  subgroups  and  the  global  cohort.
SSc  (n  =  26)  RA  (n  =  15)  Overlap  S.
(n  =  10)
Mixed  CTD
(n  =  7)
AI  Myopathy
(n  =  5)
ANCA
+  vasculitis
(n  =  4)
Total
(n  =  75)b
Demographic  characteristics
Female  sex,  n  (%)  21  (81)  11  (73)  7  (70)  6  (86)  3  (60)  2  (50)  58  (77)
Age at  CTD  diagnosis,  y  54  ±  16  54  ±  18  52  ±  10  51  ±  10  39  ±  25  61  ±  8  52  ±  16
Age at  ILD  diagnosis,  y  58  ±  18  61  ±  14  59  ±  10  55  ±  13  42  ±  23  62  ±  7  56  ±  16
HRCT at  time  of  ILD  diagnosis
NSIP,  n  (%)  19  (73)  6  (40)  8  (80)  5  (71)  3  (60)a 2  (50)  45  (60)
UIP, n  (%)  7  (27)  8  (53)  1  (10)  2  (29)  2  (40)  2  (50)  27  (36)
LIP, n  (%) 0  0  1  (10)  0  0  0  3  (4)
PFT at  time  of  ILD  diagnosis
Spirometry  pattern,  n  (%)
Normal  12  (46.2)  5  (33)  5  (50)  2  (29)  2  (40)  2  (50)  35  (46)
Restrictive 13  (50)  8  (53)  4  (40)  5  (71)  3  (60)  2  (50)  35  (46)
Obstructive 1  (3.8)  2  (13)  1  (10)  0  0  0  5  (6)
Mean FVC,  %  predicted  86.1  ±  31.8  85.3  ±  21.3  107.6  ±  29  71.7  ±  31.9  76.4  ±  20  75.5  ±  12  85  ±  27.3
Mean DLCO,  %  predicted  50.4  ±  23.7  62.4  ±  36.1  68.7  ±  18.9  49.8  ±  11.8  62.1  ±  14.2  33.7  ±  22.2  52.7  ±  23.3
Treatment
Corticosteroids,  n  (%)  22  (85)  15  (100)  8  (10)  5  (71)  5  (100)  4  (100)  65  (87)
MTX, n  (%)  6  (23)  8  (53)  4  (40)  4  (57)  0  0  23  (32)
RTX, n  (%)  2  (7.7)  1  (6.7)  1  (10)  1  (14)  4  (80)  4  (100)  13  (17.3)
TCZ, n  (%)  4  (15.4)  7  (46.7)  1  (10)  0  0  0  13  (17.3)
Mortality rate,  n  (%)  5  (19.2)  5  (33.3)  3  (30)  0  0  1  (25)  15  (20)
SSc - Systemic sclerosis; RA - Rheumatoid Arthritis; Overlap S. - Overlap syndrome; CTD - connective tissue disorder; AI myopathy -
Autoimmune myopathy; ILD - Interstitial lung disease; HRCT - High-resolution computerized tomography; NSIP - Nonspecific interstitial
pneumonia; UIP - Usual interstitial pneumoniae; LIP- Limphocytic interstitial pneumonia; PFT - Pulmonary function test; FVC - Forced
vital capacity; DLCO - Diffusing capacity for carbon monoxide; MTX - Methotrexate; RTX - Rituximab; TCZ -- Tocilizumab.
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tOne patient with anti-synthetase syndrome presented with ov
b Total includes subgroups shown plus undifferentiated CTD (n =
iased  since  this  unit  is  primarily  focused  on  CTD  with  a
ackground  in  internal  medicine.  More  importantly,  diag-
oses  were  simultaneous  in  35%  of  patients,  emphasizing
he  relevance  of  lung  involvement  in  these  conditions.  It  is
mportant  to  note  that  all  patients  had  a  definite  diagnosis
f  a  CTD,  hence  no  patient  fell  within  the  recently  suggested
efinition  of  ‘‘interstitial  pneumonia  with  autoimmune  fea-
ures’’.20
Most  patients  presented  with  a  NSIP  pattern  on  HRCT  but
ore  common  findings  such  as  pleural  thickenings  and  effu-
ions  can  point  towards  a  possible  underlying  CTD  in  an  ILD
atient.  The  majority  of  SSc  patients  had  extensive  lung
isease  on  HRCT  at  the  time  of  ILD  diagnosis,  again  rein-
orcing  the  relevance  of  this  condition,  particularly  in  light
f  the  fact  that  it  can  be  clinically  silent  during  a  significant
mount  of  time.3 Lung  biopsy  was  seldom  used  and  rarely
rovided  additional  information.
Regarding  PFT,  an  isolated  diminished  DLCO  (35%  of
atients)  may  be  the  only  abnormality.  ANCA-positive  vas-
ulitis  and  mixed  CTD  were  the  subgroups  with  the  most
mpactful  disease  at  diagnosis.  In  ANCA-positive  vasculitis
he  severity  of  the  lung  disease  was  mainly  on  account  of
 very  low  DLCO,  which  was  probably  caused  by  vasculiticPlease  cite  this  article  in  press  as:  Oliveira  RP,  et  al.  Pulmonol
isease  rather  than  ILD  per  se.
Regarding  treatment,  corticosteroids  remain  the  first-
ine  but  the  use  of  other  immunosuppressants  such  as
ycophenolate  mofetil  is  increasing.
r
w
i NSIP/OP.
d Sjögren syndrome (n = 2).
Methotrexate  was  stopped  in  most  patients  upon  ILD
iagnosis,  even  if  only  3  patients  presented  with  fibrosis
dmitted  being  related  to  it.  Over  the  years  MTX-associated
ung  disease  has  been  a  controversial  topic,  with  earlier
tudies  pointing  towards  a slightly  increased  risk  of  lung
brosis.21 MTX  was  stopped  for  most  patients  to  prevent
t  from  being  a  confounding  factor  in  the  follow-up  and
ecause  safer  and  equally  effective  drugs  were  available.
n  retrospect,  and  in  light  of  a  recent  multivariate  analysis
howing  that  there  was  no  association  between  develop-
ent  of  RA-ILD  and  MTX  use  and  that  the  drug  could  in
act  have  a  protective  role,  the  drug  could  have  been  safely
ontinued.22
Biologic  drugs  are  being  increasingly  used  in  CTD-ILD.  The
ost  used  ones  were  tocilizumab  and  rituximab  and  their
se  was  mainly  dictated  by  the  extra-pulmonary  manifesta-
ions  of  the  underlying  CTD----tocilizumab  was  predominantly
sed  in  RA  and  rituximab  for  vasculitis  and  autoimmune
yopathies.  In  this  population,  biologics  were  deemed  safe
o  start  in  patients  with  ILD  as  there  were  no  exacerbations
pon  the  start  of  biologics,  contrary  to  some  prior  reports.23
he  use  of  biologics  was  associated  with  worse  survival  but
his  is  probably  related  to  disease  severity  rather  than  drug-.  2020.  https://doi.org/10.1016/j.pulmoe.2020.01.004
elated  complications.
The  antifibrotic  nintedanib  was  used  in  2  SSc  patients
ith  extensive  lung  fibrosis,  after  positive  safety  results
n  idiopathic  pulmonary  fibrosis,24 and  might  be  a  promis-
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ing  option  for  slowing  ILD  progression  in  these  patients,
as  shown  by  the  SENSCIS  Trial.17 However,  criteria  for
nintedanib  use  in  SSc-ILD  is  up  for  debate,25 and  both
our  patients  remained  on  background  immunossuppressive
treatment.  Evidence  is  emerging  for  the  use  of  antifibrotics
in  other  CTDs.  The  recently  published  INBUILD  Trial  showed
that  nintedanib  leads  to  a  lower  annual  rate  of  decline  in
FVC  in  patients  with  progressive  fibrosing  interstitial  lung
diseases,  including  patients  with  autoimmune  diseases,  the
majority  of  them  with  RA-ILD  and  also  including  patients
with  mixed  CTD.26
With  20%  mortality  rate  and  a  mean  survival  of
37.8  ±  20.9  months,  ILD  constitutes  an  important  burden
on  CTD  patients  and  significantly  impacts  their  prognosis.
In  this  cohort,  pH  was  the  single  most  important  mortality
predictor  (OR  14.41,  p  =  0.006).
Even  though  this  article  provides  an  overview  of  the
general  population  encountered  at  an  autoimmune  diseases
unit,  some  particular  subsets  of  patients  are  not  as  strongly
represented  in  the  cohort  (e.g.  autoimmune  myopathies)
and  this  could  lead  to  an  underrepresentation  of  more  spe-
cific  and  less  common  findings,  as  is  the  case  of  organizing
pneumonia.  At  the  other  end,  it  could  lead  to  an  overrepre-
sentation  of  rare  findings,  such  as  the  LIP  pattern  in  a  patient
with  polymyositis.  Heterogeneity  regarding  the  underlying
CTDs,  disease  duration,  treatment  and  follow-up  and  the
retrospective  nature  of  the  study  may  limit  the  interpre-
tation  of  some  of  the  results.  The  data  presented  reflects
the  clinical  expertise  of  a  single  institution  that  has  its  main
focus  on  CTD  and  may  not  be  fully  representative  of  prac-
tices  elsewhere.
Conclusion
To  the  best  of  our  knowledge  this  is  the  largest  cohort  of
CTD-ILD  presented  by  a  Portuguese  centre.
ILD  is  a  potential  complication  of  virtually  every  CTD,
constitutes  an  important  burden  on  these  patients  and
significantly  impacts  their  prognosis.  A  systemic  and  multi-
disciplinary  overview  is  essential  for  adequate  management,
in  order  to  fill  in  the  remaining  gaps  regarding  early  diagno-
sis,  follow-up  and  treatment  of  these  patients.
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